Exhibit 99.2

PROFOUND MEDICAL CORP.

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2022

PRESENTED IN US DOLLARS (000s)

Profound Medical Corp.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Profound Medical Corp.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Profound Medical Corp.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Profound Medical Corp.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Profound Medical Corp.

Notes to Interim Condensed Consolidated Financial Statements

June 30, 2022

In USD (000s)

(Unaudited)

Profound Medical Corp. (Profound) and its subsidiaries (together, the Company) were incorporated under the Ontario Business Corporations Act on July 16, 2014. The Company is a medical technology Company developing treatments to ablate the prostate gland, uterine fibroids, osteoid osteoma and nerves for palliative pain relief for patients with metastatic bone disease.

The Company’s registered address is 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, L4W 5K5, Canada.

Basis of preparation

The Company prepares its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS), applicable to the preparation of interim condensed consolidated financial statements, including International Accounting Standards (IAS) 34, Interim Financial Reporting. These interim condensed consolidated financial statements are presented in US dollars and should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2021, which were prepared in accordance with IFRS.

The Board of Directors approved these consolidated financial statements on August 4, 2022. These consolidated financial statements comply with IFRS.

The interim condensed consolidated financial statements were prepared on a going concern basis under the historical cost convention, except for the derivative financial instrument which is measured at fair value.

COVID-19

The COVID-19 outbreak has been declared a pandemic by the World Health Organization. COVID-19 is altering business and consumer activity in affected areas and beyond. The global response to the COVID-19 pandemic has resulted in, among other things, border closures, severe travel restrictions, the temporary shut-down of non-essential services and extreme fluctuations in financial and commodity markets. Additional measures may be implemented by one or more governments in jurisdictions where the Company operates. These measures have caused material disruption to businesses globally, resulting in an economic slowdown. The extent to which COVID-19 and any other pandemic or public health crisis impacts the Company’s business, affairs, operations, financial condition, liquidity, availability of credit and results of operations will depend on future developments that are highly uncertain and cannot be predicted with any meaningful precision, including new information which may emerge concerning the severity of the COVID-19 virus and the actions required to contain the COVID-19 virus or remedy its impact, among others.

Further, from an operational perspective, the Company’s employees, direct sales and marketing teams and distribution partners, as well as the workforce of vendors, services providers and counterparties with which the Company does business, may also be adversely affected by the COVID-19 pandemic or efforts to mitigate the pandemic, including government-mandated shutdowns, requests or orders for employees to work remotely, and other physical distancing measures, which could result in an adverse impact on the Company’ ability to conduct its businesses, including its ability to cultivate adoption of the TULSA-PRO^® technology, support clinical trials, support clinical customers with the TULSA-PRO^® procedures and increase the utilization of the systems and one-time-use devices.

To date, the economic downturn and uncertainty caused by the COVID-19 pandemic and global measures undertaken to contain its spread have affected all of the Company’s operations to some extent and, in particular, have caused volatility in demand for the TULSA-PRO^® and SONALLEVE^® systems and the one-time-use devices related thereto. This has resulted in a reduction in anticipated sales and led to delays in the Company’s expectations regarding the rate at which agreements for new system user sites will be entered into and when user sites will become operational for the initiation of patient treatments. Despite the COVID-19 pandemic, patient treatments are continuing and Profound continues to identify potential new system user sites. The Company continues to evaluate the current and potential impact of the COVID-19 pandemic on its business, affairs, operations, financial condition, liquidity, availability of credit and results of operations.

The financial impacts from COVID-19 during the period has affected Profound’s ability to collect payments due to continuous lockdowns and hospital restrictions, which have impeded our efforts to install our systems and has delayed corresponding collections. Profound continues to work with local authorities and team members located within these countries to help expedite the process.

The trade and other receivables balance comprises the following:

Trade receivables past due represents amounts not collected beyond the customer’s contractual terms. The Company applies the simplified approach to provide for expected credit losses prescribed by IFRS 9, which permits the use of the lifetime expected loss provision for all trade receivables. At June 30, 2022 and December 31, 2021 there were no trade receivables that were past due.

Management continually reviews the future cash flows used in the calculation of the amortized cost of its trade and other receivables. Due to the ongoing COVID-19 pandemic and access to customer locations, certain trade and other receivables are expected to have a longer repayment term due to the payment term being based on installation of the device. The Company recognized $168 and $212 of interest income for the three and six months ended June 30, 2022, respectively ($nil and $nil for the three and six months ended June 30, 2021, respectively). During the three months ended June 30, 2022 and subsequent to June 30, 2022, certain trade and other receivables where the amortized cost had been previously revised were collected. As a result, all remaining interest income accretion was recognized on an accelerated basis. Those trade and other receivables that are anticipated to be collected after one year are classified as non-current.

During the three and six months ended June 30, 2022, $552 and $1,179 (three and six month periods ended June 30, 2021, $1,564 and $2,004, respectively) of inventory was recognized in cost of sales. The Company increased its inventory provision by $15 and $21 during the three and six months ended June 30, 2021 (decreased the three and six month periods ended June 30, 2021 - $6 and $9). There were no other inventory writedowns charged to cost of sales during the period ended June 30, 2022.

Property and equipment consists of the following:

Intangible assets consist of the following:

The Company leases office premises in Mississauga, Canada and Beijing, China. These lease agreements are typically entered into for three to ten-year periods.

Common shares

The Company is authorized to issue an unlimited number of common shares.

Issued and outstanding (with no par value)

Warrants

A summary of warrants outstanding is shown below:

Share options

Compensation expense related to share options for the three and six months ended June 30, 2022 was $1,203 and $1,700, respectively (three and six month periods ended June 30, 2021 was $1,552 and $2,632, respectively).

A summary of the share option changes during the period presented and the total number of share options outstanding as at those dates are set forth below:

The following table summarizes information about the share options outstanding as at June 30, 2022:

Long-term incentive plan

Share-based compensation expense related to long-term incentive plan (LTIP) for the three and six months ended June 30, 2022 was $388 and $766 (three and six month periods ended June 30, 2021 was $149 and $166, respectively).

A summary of the RSUs changes during the period are set forth below:

Foreign currency risk occurs as a result of foreign exchange rate fluctuations between the time a transaction is recorded and the time it is settled.

The Company purchases goods and services denominated in foreign currencies and, accordingly, is subject to foreign currency risk. The Company’s financial instruments denominated in foreign currencies are shown below in US dollars.

As at June 30, 2022, if foreign exchange rates had been 5% higher, with all other variables held constant, comprehensive loss would have been $2,710 higher, mainly as a result of the translation of foreign currency denominated cash, trade and other receivables, accounts payable and accrued liabilities, other liabilities and lease liabilities. The Company does not use derivatives to reduce exposure to foreign currency risk.

The following table shows the calculation of basic and diluted loss per share:

Of the 1,848,336 (June 30, 2021 – 2,021,933) share options, 143,911 (June 30, 2021 – 218,983) RSUs and 724,983 (June 30, 2021 – 1,093,708) warrants not included in the calculation of diluted loss per share for the period ended June 30, 2022, 1,737,898 (June 30, 2021 – 1,743,892) were exercisable.

Key management includes the Company’s directors and senior management team. The remuneration of directors and the senior management team was as follows:

Executive employment agreements allow for additional payments in the event of a liquidity event, or if the executive is terminated without cause.

The Company’s operations are categorized into one industry segment, which is medical technology focused on magnetic resonance guided ablation procedures for the treatments to ablate the prostate gland, uterine fibroids, osteoid osteoma and nerves for palliative pain relief for patients with metastatic bone disease. The Company is managed geographically in Canada, Germany, USA, China and Finland.

For the three months ended June 30, 2022:

For the six months ended June 30, 2022:

For the three months ended June 30, 2021:

For the six months ended June 30, 2021:

Other financial information by segment as at June 30, 2022:

Other financial information by segment as at December 31, 2021:

(11)